Loading financial data...

MADRIGAL PHARMACEUTICALS, INC. (MDGL) Financial Statements | Global Financial Data

MADRIGAL PHARMACEUTICALS, INC.

MDGLSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1157601

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	—	—	—
Cost of Goods and Services Sold	—	$0.00	—	—	—
Selling, General and Administrative Expense	$108.1M	$48.1M	—	—	—
Operating Expenses	$380.5M	—	$242.5M	$206.7M	$95.0M
Operating Income (Loss)	-$380.5M	-$293.6M	-$242.5M	-$206.7M	-$95.0M
Interest Expense	—	—	$0.00	$0.00	—
Other Nonoperating Income (Expense)	$0.00	—	—	—	—
Income Tax Expense (Benefit)	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.0B	$640.5M	$362.6M	$273.3M	$287.0M
Assets, Current	$1.0B	$637.3M	$361.4M	$271.7M	$285.2M
Cash and Cash Equivalents, at Carrying Value	$100.0M	$99.9M	$331.5M	$36.3M	$54.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$53.8M	$0.00	—	—	—
Inventory, Net	$34.1M	$0.00	—	—	—
Liabilities	$287.9M	$235.2M	$165.2M	$77.2M	$47.0M
Liabilities, Current	$169.3M	$118.5M	$115.9M	$76.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$324.2M	-$224.9M	-$183.9M	-$157.6M	-$41.6M
Net Cash Provided by (Used in) Investing Activities	-$502.5M	$206.7M	-$5.1M	$159.8M	$30.7M
Net Cash Provided by (Used in) Financing Activities	$595.1M	$313.5M	$171.2M	$5.1M	$235.0K
Payments to Acquire Property, Plant, and Equipment	$1.5M	$217.0K	$209.0K	$334.0K	$172.0K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)